Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
NCT03389893 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE4 · terminated · last registry update 2021-10-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to inability to meet accrual goals within the funding period.” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL4R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-09-28Results posted on the registry: Sanofi, Dupilumab SAR231893 + Placebo (NCT04202679)
- 2022-09-19Phase 3 first posted: Emory University, Dupilumab + Placebo (NCT05545072)
- 2022-09-10Phase 3 first posted: Wei-Che Ko, Squaric Acid Dibutyl Ester + Dupilumab (NCT05535738)
- 2022-09-02Phase 3 first posted: Sanofi, Dupilumab (NCT05526521)
- 2022-07-28Results posted on the registry: Regeneron Pharmaceuticals, Dupilumab + Matching placebo (NCT03346434)
- 2022-07-22Results posted on the registry: Sanofi, Dupilumab SAR231893 (NCT04447417)
- 2022-07-08Results posted on the registry: Pfizer, Abrocitinib 200 mg + Dupilumab 300 mg (NCT04345367)
- 2022-05-19Results posted on the registry: Regeneron Pharmaceuticals, Dupilumab (NCT03793608)
- 2022-05-11Phase 3 first posted: Eli Lilly and Company, Lebrikizumab (NCT05369403)
- 2022-03-29Results posted on the registry: Sanofi, SAR440340 + Dupilumab (NCT03387852)
- 2022-03-02Phase 3 first posted: Sanofi, Dupilumab + Placebo (NCT05263206)
- 2022-02-14Results posted on the registry: Icahn School of Medicine at Mount Sinai, Dupilumab + Placebo (NCT03359356)
- 2022-02-02Results posted on the registry: AbbVie, Upadacitinib + Dupilumab (NCT03738397)
- 2021-11-01Results posted on the registry: Regeneron Pharmaceuticals, REGN3500 + Dupilumab (NCT03736967)
- 2021-11-01Also stopped (terminated): Regeneron Pharmaceuticals, REGN3500 + Dupilumab (NCT03736967)
- 2021-10-20Results posted on the registry: Sanofi, Dupilumab + Placebo (NCT02948959)
- 2021-10-15Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dupilumab (NCT03886493)
- 2021-10-15Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dupilumab (NCT03886493)
- 2021-04-05Results posted on the registry: Sanofi, Dupilumab + Placebo (NCT03912259)
- 2021-01-19Results posted on the registry: Pfizer, PF-04965842 100 mg + PF-04965842 200 mg (NCT03720470)
- 2020-12-24Phase 3 first posted: Sanofi, Dupilumab SAR231893 + Placebo (NCT04684524)
- 2020-12-23Phase 3 first posted: Sanofi, Dupilumab SAR231893 + Placebo (NCT04681729)
- 2020-12-22Phase 3 first posted: Sanofi, Placebo + Dupilumab SAR231893 (NCT04678882)
- 2020-11-02Results posted on the registry: Sanofi, Dupilumab (NCT02134028)
- 2020-10-05Results posted on the registry: Regeneron Pharmaceuticals, Dupilumab (NCT02407756)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision